« Return to News | Study Conduct

AstraZeneca selects Cambridge, U.K. for R&D center and corporate headquarters

Thursday, June 20, 2013 11:00 AM

AstraZeneca is building a new $514 million global R&D center and corporate headquarters on the Cambridge Biomedical Campus. By 2016, the new site will house 2,000 employees.

The investment is part of AZ’s move to create strategic global R&D centers in the U.K., U.S. and Sweden to improve pipeline productivity and establish AZ as a global leader in biopharmaceutical innovation.

The site will bring together small molecule and biologics R&D activity, opening up opportunities to small and large molecule combinations. The Cambridge Biomedical Campus will be the new U.K. home for biologics research and protein engineering carried out by MedImmune, AZ’s biologics arm.

The site also will become the company’s largest center for oncology research, as well as cardiovascular and metabolic disease, respiratory, inflammation and autoimmune disease and central nervous system research. The facility also will hold preclinical capabilities including medicinal chemistry and high-throughput screening.

The Cambridge Biomedical Campus is home to research, academic and healthcare organizations including the University of Cambridge school of Clinical Medicine, Addenbrooke’s Hospital, the Medical Research Council Laboratory of Molecular Biology, the Wellcome Trust-MRC Institute of Metabolic Science and the Cancer Research U.K. Cambridge Institute.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.